Abortion Pill Probe Explodes On Capitol Hill

Washington is once again colliding over who really gets to police powerful industries—the people’s elected representatives, or an unelected health bureaucracy that approved a life-ending drug with contested safety reporting.

Quick Take

Sen. Josh Hawley opened a Senate investigation into the two main mifepristone manufacturers, Danco Laboratories and GenBioPro, demanding records by April 24.
Hawley’s inquiry seeks documents on adverse events, internal risk awareness, and communications with regulators tied to complications like hemorrhage, infection, and sepsis.
The probe runs alongside Hawley’s bill to revoke the FDA approval of mifepristone for abortion use, escalating a post-Dobbs fight over medication abortion.
Safety claims are sharply disputed, with EPPC research cited by Republicans and pushback from abortion-pill advocates and some researchers questioning methodology.

Hawley targets pill makers with document demands and a public reporting line

Sen. Josh Hawley (R-Mo.), chairing the Senate Judiciary Subcommittee on Crime and Counterterrorism, has launched a formal investigation into Danco Laboratories and GenBioPro, the two primary manufacturers of mifepristone. Letters sent in the week of March 19 request documents on adverse events, what company officials knew internally about risks, and communications with regulators. Hawley also announced a hotline for women to report harms, broadening the inquiry beyond Washington paperwork.

Hawley set an April 24 deadline for materials and framed the action as a consumer-safety and accountability effort, arguing Congress must act when regulators fail to demand transparency. While the Senate cannot directly practice medicine, it can examine whether companies and agencies have provided complete information to the public. At this stage, the available reporting shows no public responses from the companies to the Senate demands, leaving key questions unresolved until records are produced.

The bill strategy: revoke FDA approval and invite lawsuits

On March 11, Hawley introduced the “Safeguarding Women from Chemical Abortion Act,” aiming to revoke the FDA’s approval of mifepristone for abortion use and to prohibit its use for abortions nationally. The proposal also seeks to open the door for lawsuits against manufacturers—an approach that fits a wider conservative push to restore consequences when corporate actors allegedly minimize risks. Rep. Diana Harshbarger (R-TN) announced companion legislation in the House.

Hawley’s legislative push arrives as the country’s abortion policy remains fragmented after Dobbs, with states setting rules while medication abortion becomes the dominant method in many places. Research cited in the reporting places mifepristone’s FDA approval in 2000 and notes that the drug was used in a majority of U.S. abortions by 2023, heightening the stakes of any national policy change. That scale also explains why this fight is now centered on data quality, reporting rules, and oversight authority.

Competing safety narratives and what the investigation can actually clarify

The dispute pivots on which evidence the public should trust. Hawley and allied pro-life groups cite research from the Ethics and Public Policy Center (EPPC) claiming serious adverse events occur at far higher rates than what the FDA label reflects. Critics—including abortion-pill advocates like Plan C—counter that the EPPC work is not peer-reviewed and that decades of studies support mifepristone’s safety and effectiveness, arguing the claims rely on flawed definitions or selective data.

This is where the Senate inquiry could matter, regardless of where readers stand on abortion. If companies and regulators possess clearer adverse-event data, internal risk assessments, or communications that explain how safety claims were generated, those records can help the public judge whether existing guardrails are real or rhetorical. If the record is thin—or if reporting systems are too weak to capture outcomes—then policymakers are debating life-and-death questions with incomplete information.

The executive branch review adds pressure—without guaranteeing action

The reporting also places the investigation inside a larger federal tug-of-war. HHS Secretary Robert F. Kennedy Jr. has ordered a review of mifepristone safety after calling the EPPC findings “alarming” during a Senate hearing, but timelines and potential outcomes remain unclear. Meanwhile, other coverage suggests political obstacles for any nationwide ban, including uncertainty about how the White House would treat sweeping legislation, even under a Republican administration.

Josh Hawley opens investigation into abortion pill companies, creates hotline for victims – LifeSite https://t.co/FHFwqUyTzJ

— Valerie (@ValerieRies) March 24, 2026

For conservative voters already weary of unaccountable agencies, the core issue is not only abortion—it is whether federal health decisions that affect millions can be insulated from democratic scrutiny. Hawley’s approach uses Congress’s oversight powers to force disclosure first, then fight policy second. With the April 24 deadline approaching, the next concrete milestone is whether Danco and GenBioPro comply and whether the resulting record confirms, contradicts, or complicates the competing safety claims now driving this national showdown.